ArticleDiscover oncology2025
Development and validation of a nomogram for predicting postoperative survival in patients with multifocal hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the fifth most common malignant tumor and the third leading cause of cancer-related death worldwide. Despite the significance of multifocality in HCC (M-HCC), most studies have predominantly treated it as a prognostic factor, lacking in-depth investigation into its prognostic implications. This retrospective study aims to integrate clinical and laboratory examinations to construct a predictive model that more accurately forecasts the prognosis of patients with M-HCC. This aims to guide personalized treatment strategies and improve overall survival rates.
methodsWe applied the Lasso and cross-validated Lasso (CV-Lasso) combined with Random Forest analysis to explore the prognostic factors influencing M-HCC. Simultaneously, we utilized the identified prognostic factors to construct a Nomogram. This Nomogram assigns scores based on the magnitude of the impact of each factor on prognosis, enabling the prediction of postoperative survival rates for patients. Subsequently, the model-derived risk scores categorized patients into low-risk and high-risk groups, and Kaplan-Meier curves were generated.
resultsThe patients, who were enrolled, were divided into training and validation sets. Factors influencing the prognosis of M-HCC were identified through Lasso, cross-validated Lasso, and Random Forest analyses, revealing seven key factors: Age, Antiviral, Child-Pugh, Cirrhosis, White Blood Cell (WBC), Platelets (PLT), and Thrombin Time (TT). Nomograms were constructed based on these factors to predict 3-year, 5-year, and 8-year survival rates. ROC curves confirmed the predictive capability of various factors, with larger areas under the curve at 5 (AUC = 0.653) and 8 years (AUC = 0.733). Kaplan-Meier curves stratified patients into low-risk and high-risk groups, showing significantly higher survival times in the low-risk group (p < 0.0001).
conclusionsPostoperative antiviral treatment for patients with M-HCC, aimed at enhancing immune function and protecting liver function, has been shown to extend patient survival. Simultaneously, factors such as Child-Pugh, age, and Cirrhosis in patients with M-HCC have been associated with a decrease in postoperative survival time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.